FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005, x108

Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

More patients to benefit from STENTYS technology

PRINCETON, N.J., and PARIS, February 8, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the higher-price reimbursement in Germany received in 2011 for its drug-eluting stent was expanded to all coronary indications in 2012, allowing even more patients to benefit from its technology.

“This indication expansion decision by the Institute for the Hospital Remuneration System (InEK) is yet another evidence of the value of our innovation and will strengthen our commercial presence in Germany, the largest European stent market,” said Gonzague Issenmann, CEO and co-founder of STENTYS.

The STENTYS Self-Apposing™ Stent represents a major breakthrough: it solves the stent sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition.

About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing™ stent adapts to the anatomic changes of the artery in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

###